The FDA's new 2026 guidelines are poised to significantly reshape major US biotech symposiums, demanding proactive adaptation from industry leaders and innovators to navigate evolving regulatory landscapes and foster critical advancements.

Key policy discussions from US biotech events in the last half of 2024 are shaping the industry's trajectory for 2025, focusing on regulatory frameworks, investment incentives, and ethical considerations.